---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007473"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T05:07:38.976321+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CMS grants pass-through payment status for Heron's APONVIE effective April 1, 2023

## Summary
- CMS approves three-year transitional pass-through status for APONVIE under C-code C9145 starting April 1, 2023.
- APONVIE will be reimbursed separately outside surgical bundle at ASP+6% in HOPD and ASC settings.
- APONVIE is the only PONV drug with Medicare reimbursement in both outpatient settings; launched March 6, 2023.
- Over 70% of surgery opportunity is in outpatient settings; CEO says status facilitates patient access and billing.

## SEC filing metadata
- accession: 0000950170-23-007473
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023007473/0000950170-23-007473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023007473/hrtx-20230313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007473
- JSON: https://secwatch.observer/filing/0000950170-23-007473.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.